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Abstract
Young women are at the maximum risk of human papilloma virus (HPV) infection 
which are asymptomatic in a majority of cases and spontaneously get cleared. Women 
in the age between 20 and 35 years are more active sexually and especially in the devel-
oping nations, this age group forms a major cohort among the population of pregnant 
women. The changed hormonal milieu and immune response during pregnancy 
might favor presence or persistence of HPV infection, while at the same time natural 
clearance also takes place during pregnancy with an unknown mechanism. Various 
HPVs have been reported to be associated with preterm rupture of membranes 
(PROM), fetal growth restriction (FGR), preeclampsia, placental abnormalities and 
preterm delivery in several populations. The risk factors involved in the intrauterine 
environment affects fetal development and thus increase the development risk of 
specific diseases in adult life as per the hypothesis of the fetal origins of adult disease 
(FOAD). The structural and molecular changes in the feto-maternal interface support 
and protect the semiallogeneic fetus from immune-mediated or inflammatory injury. 
On the other hand, the trophoblast cells of placenta facilitate the replication of HPV 
and the affliction of placenta and the vaginal infection can directly be associated 
with pregnancy outcomes. So, to optimize better child health care and reproductive 
outcomes, HPV screening might help during pregnancy. It is therefore important to 
understand how the HPV is affecting the early pregnancy and immune cells within 
the feto-maternal interface are educated for self-clearance to fulfill their biological 
functions or prevalence to affect the pregnancy outcomes and how the persistence of 
HR-HPV infection overtime increases the development of cervical cancer risk.
Keywords: pregnancy, self clearance, feto-maternal cell trafficking, HPV vaccine, 
cervical cancer
1. Introduction
The most common sexually transmitted infectious conditions across the 
globe are human papilloma virus (HPV) infections which is responsible for the 
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development of cervical cancer. The infection of HPV does not always lead towards 
the neoplastic disease which suggests that the clearance or acquisition of HPV infec-
tions may depend on the interpersonal variations in the immune system as well as 
environmental or viral factors. For example, a well-established cervical cancer risk 
factor is parity. However, the influence of pregnancy in the natural history of HPV 
infection and thus the development of cervical neoplasia and its exact mechanism is 
not known [1].
At the beginning of the pregnancy, immune modulation and induction of 
tolerance are required for successful implantation allowance but as the pregnancy 
progresses a responsive immune system is responsible for a successful pregnancy 
which can protect both the fetus and the mother against environmental insults 
whenever there is a necessity arises. Indeed the maternal immune system reinforces 
networks that can respond according to the recognized danger signals and eliminate 
them appropriately promoting repair when needed. Not only the maternal immune 
system but also the actively developing immune system in the fetal-placental unit 
can modify further the maternal immune response and the reaction of the mater-
nal immune system to the environment. So, the immunity during pregnancy is 
dynamic and unique which can be modulated as per the requirement and definitely 
not suppressed [2].
Several studies have proven the idea incorrect that constant immunosuppres-
sion is crucial for a successful pregnancy which demonstrates that inhibition of key 
signaling pathways such as pathways mediated by FAS; FAS ligand and deletion of 
immune cells at the implantation site are detrimental to pregnancy which may lead 
to pregnancy loss [3, 4]. The deletion of specific decidual NK cells leads to poor 
endometrial vascularity and obstruct the invasion of the trophoblast [5]. Thus, for a 
successful pregnancy the presence of immune infiltrates is required which suggests 
that the immune cells are not recruited to the decidua as a response to a ‘non-self ’ or 
‘foreign’ fetus but recruited actively to facilitate proper implantation and promote 
successful pregnancy.
During pregnancy and postpartum, different levels of hormonal changes and 
changes in the immunity may be responsible for the modulation of the natural 
history of the HPV infection. There are differences in the status of HPV infec-
tion during pregnancy and reduction in the number of HPV positive cases during 
postpartum period have been reported by various authors [6]. Though the dynam-
ics of HPV infection during pregnancy is not well understood and the information 
remains controversial. The clearance and persistence of HPV during and after 
pregnancy have been studied by very few authors [7].
HPV infection in most cases naturally disappears in a short relative time period 
and risk of disease development in that case is very less. As pregnancy affects the 
host immune system, it is believed that pregnancy reduces the seroreactivity against 
infection of HPV. The upstream regulatory region of HPV18 has been reported to be 
activated by estrogen and progesterone which alters the clearance rate of HPV com-
pared to non-pregnant women [8]. HPV genotypes and viral characteristics such as 
population distribution and evasive ability play an important role during persistent 
infection. However, how the HPV genotype specific reaction of the host immune 
system and the sexual behavior of pregnant women affect the rates of infection in 
case of persistent cases and how it is related to the host in not clear [9].
In pregnancy, the pregnant mother which is an adult organism is exposed to 
the fetus which is partly an extremely young organism and this phenomenon can 
be viewed similar to a natural state known as parabiosis in which organisms share 
partly blood systems. However, the fetus may have restoring effect on the maternal 
system. It has been reported that the regenerative capacity of the aged liver and 
other organs in mice model is restored by pregnancy [10].
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There are controversial results on the risk of HPV infection in pregnant 
women. A higher HPV prevalence has been reported in few studies in pregnant 
women, whereas, some claimed there are no statistical difference among the age 
matched non-pregnant women [9]. Moreover, there are no studies on estimating 
the trimester, age and type specific prevalence of cervical HPV DNA in pregnant 
women.
This chapter will focus on the incidence of HPV infection in pregnant women 
population, the reason behind higher incidence rates in early pregnancy, the 
possible mechanisms responsible for self-clearance and non-clearance of HPV in 
pregnant women, immune mechanisms playing role in pregnancy, feto-maternal 
cell trafficking and how HPV affects the pregnancy outcomes. Furthermore, we 
will also discuss the potential of HPV infection during pregnancy can lead to the 
development of cervical cancer and therapeutic strategies.
2. Incidence of HPV infection in pregnant women population
Highest incidence rates have been reported in young adults just after the onset 
of their sexual activity [11]. In young women between the age group of 17 and 
24 years, longitudinal studies reported incidence rates of HPV infection ranging 
from 15.7 to 29.4 of all types per 1000 women-months [12]. Women in their thir-
ties showed a lower incidence rate in cohort studies which is between 5.2 and 13.4 
any type HPV infection per 1000 women-months [12]. The prevalence is likewise 
higher in younger age groups than older. The global HPV prevalence estimated by 
a multi-country meta-analysis is 11.7% (with confidence interval 95% 11.6–11.7%) 
with normal cytology in women with an important variation within and between 
geographic regions. At round 25 years the prevalence peaks and decreases thereaf-
ter. It has been reported that at around 45 years a smaller second peak is observed 
[13, 14]. It has also been reported in various studies that within 1–2 years of HPV 
infection almost 80% of them resolve spontaneously [15]. Various studies suggested 
that during pregnancy it is more likely to acquire and progress HPV infection [16] 
which regresses after delivery [6, 7, 17, 18].
Whereas, Liu et al. [16] reported that in pregnant women the HPV prevalence 
varies from 9.58 to 46.67% and in age-matched non-pregnant women the preva-
lence varies from 8.9 to 23.5%, with a summary estimate of 16.82 and 12.25% 
respectively and there are significant differences between the summary estimates. 
In Asia, North America and Europe, it has been reported that the HPV prevalence 
rates are significantly higher in pregnant women as compared to those in non-
pregnant women and the pregnant women in North America as compared to those 
in Europe and Asia are more susceptible to HPV infection [16]. As per the meta-
analytical data showed by Liu et al. [16], the prevalence rates of HPV infection in 
pregnant women in North America, Australia, Europe and Asia were 30.37, 36.60, 
13.19 and 15.72% respectively which showed a worldwide significant difference. 
In pregnant women aged 25, 25–29 and ≥ 30 years the prevalence rates of HPV 
infection were 23.94, 13.34 and 14.79% respectively and in non-pregnant women 
the prevalence rates were 18, 12.08 and 11.43% in respective three age groups [16]. 
The most frequently identified HPV types in pregnant women have been reported 
are HPV-16 with 3.86% prevalence rate, HPV-6 with 2.45% prevalence rate, HPV-
18 with 1.80% prevalence rate and HPV-11 with 1.76% prevalence rate which is as 
same as the prevalence rates in non-pregnant women of these HPV types. In the 
three trimesters the HPV prevalence rates reported are 18.20, 14.38 and 19.32% and 
the odd ratios are 1.59, 1.20 and 1.71 respectively as compared to the non-pregnant 
women population.
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Studies conducted in Hong Kong and Hungary showed that in asymptomatic 
pregnant women HPV-16 is the most common type and HPV-6,-18,-11,-58,-31 
and − 33 are the other common HPV types [19]. Whereas, in non-pregnant women 
the sequence is bit different such as HPV-16, -6, -11, -18, -58, -33 and -31 and in 
women with normal cytology worldwide the sequence reported is HPV-16, -18, -31, 
-58 and -52 [16].
Specific to genital tract infections, HPV types are classified into three risk 
categories based on their relative malignant potential such as HPV-6, -11, -40, -42, 
-43, -44 are low risk; HPV-31, -33, -35, -51, -52 are intermediate and HPV-16, -18, 
-45, -56 are high risk types. Young women between the ages of 10 and 35 years are 
reported to be at the maximum risk of HPV infection which are asymptomatic 
in majority of the cases and spontaneously get cleared may be due to the strong 
immune system. The reason being this is the age when women are sexually more 
active. A major cohort of the pregnant population is formed by this age group in the 
developing nations. The changed immune response and hormonal milieu during 
pregnancy might favor the presence or persistence of the HPV infection. Niyibizi 
et al. [18] reported the prevalence of HPV infection in pregnant women with a 
wide variation from 5.5 to 65%. Various HPVs in several populations have been 
reported to be associated with adverse pregnancy outcomes such as preeclamsia, 
preterm rupture of membranes (PROM), preterm delivery, fetal growth restriction 
and placental abnormalities. However, no such data on the association of the HPV 
infection in pregnancy and its outcome from the Indian subcontinent is available 
till date [20].
3. The reason behind higher incidence rates in early pregnancy
3.1 Maternal immunity during pregnancy
Starting at the conception and towards the course of completion with labor and 
birth enormous transformations the uterus has to undergo in pregnancy. In order 
to achieve blastocyst stage embryo development for a newly fertilized egg and 
successful invasion into the uterine tissue, there is a requirement of finely balanced 
subsets of immune cells and their soluble mediators. Mainly genetics determine the 
developmental potential of the blastocyst. However, the optimal environment of 
the uterus determines the viability and competence of the blastocyst to become a 
fully developed fetus and on-time delivery achievements which in turn reflects the 
maternal immune response quality.
It has been claimed that pregnancy is a state of mild immunosuppression due 
to the reduction in the helper T-cell type 1 cell mediated response or decrease in 
natural killer cells. Sillman and Sedlis in the year 1987 reported that a higher inci-
dence of cervical neoplasia is found in immunosuppressed women [15]. A steroidal 
hormone receptor binding element present on the transcriptional promotor of 
HPV-16 as reported by Gloss et al. is responsible for promotion of HPV transcrip-
tion which suggests an involvement of hormonal activation of replication of HPV 
[21]. Observation from various studies indicated that the temporary altered immu-
nity state and the increased steroidal hormonal levels during pregnancy might have 
an influence of the subsequence progression of the disease development effecting 
on HPV replication [16].
Fetus inherits 50% genome from the father that leads to the expressing of anti-
gens which are acknowledged as foreign by the maternal immune system. To accom-
modate the semi-allogeneic fetus within the immunocompetent mother’s body a 
range of complex processes take place [22]. The physiological and immunological 
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changes during pregnancy marks it a unique condition that makes the mother 
and the fetus more susceptible to certain infectious diseases, risk of congenital 
anomalies and the risk of more serious outcomes in other diseases. These changes 
are mainly driven by the cytokines, hormones and immune cells that lead to the 
modification of the immune system as well as the structural changes by remodeling 
of the endometrium [23]. In the 1950s, it was initially proposed that the induction 
of general immunosuppression during pregnancy allows the tolerance of the semi-
allogeneic fetus and since then several hypotheses has been proposed explaining the 
reason why the fetus is not rejected by the maternal immune system (Figure 1).
On the contrary, after the natural infection pregnant women are capable 
of inducing immune responses and immune memory which is similar to non-
pregnant women which proves the above hypothesis wrong [24]. Various studies 
have reported that the modulation of the immune system rather than active 
suppression is observed during pregnancy. Over the course of pregnancy, the 
progressive increase of the concentrations of steroidal hormones such as proges-
terone and estrogens induce a shift in the balance of pro and anti-inflammatory 
responses. During the first trimester of pregnancy which is called “open wound 
phase” the pro-inflammatory responses are prominent and in the second and the 
third trimester phases where the body prepared for deliver the anti-inflammatory 
responses are prominent [22]. Thus, it is clear that why the severity of certain 
diseases such as multiple sclerosis, rheumatoid arthritis induced by the inflam-
matory responses are often gets reduced during the third trimester of pregnancy 
and diseases which are controlled by the inflammatory responses such as malaria, 
influenza and lupus are increased during this phase [25]. There is a shift from Th1, 
which is oriented towards cell-mediated immunity, towards Th2, which is oriented 
towards the hormonal immunity, responses is observed which is associated with an 
alteration of the balance between type1 and type 2T helper cells and this transition 
is needed for the development of a healthy fetus. The suppression of cytotoxic T 
lymphocytes and stimulation of B lymphocytes to further increase the production 
of antibodies that are potential to be transferred to the fetus is controlled by these 
Th2-skewed responses. The findings of Mor et al. [22] and Chaouat et al. [24] 
suggested that the placenta is capable of interaction and response to pathogens 
which makes it an active immunological site. At the feto-maternal interphase, 
the immune mechanisms contribute to protect the fetus from rejection provid-
ing required cytokines and growth factors for implantation of the fetus in the 
Figure 1. 
Accommodation of the semi-allogenic fetus in the maternal system.
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placenta. The placenta can generate signals which may modulate the responses 
of the maternal immune system to pathogens which leads to a new paradigm that 
there is a combination of signals and responses originating both from the feto-
placental unit and the maternal immune system which decides the overall immu-
nological responses during pregnancy (Figure 2) [26].
3.2 Anatomical changes during pregnancy
The increased susceptibility to infection of pregnant women during pregnancy 
may be due to the immunological and anatomical changes of the uterine canal. Like 
other human viruses, the placenta or the cells of the fetal origin may get infected by 
HPV. The presence of HPV has been reported in the polymorphonuclear cells which 
suggest that the passage of virus through feto-maternal barrier may be allowed by 
the transfer of the maternal cells [27]. It has also been reported that the trophoblast 
cells are broadly permissive in vitro for HPV and within the trophoblast cell cultures 
this virus is able to complete its life cycle [28, 29].
In the uterine mucosa, especially in the postovulatory phase there is an increase 
in the circulating progesterone levels which initiates a cascade of molecular and 
cellular events that allows the initial anchor of the embryo to the epithelial layer of 
the endometrial surface further leading to the coordination of the invasion of the 
extra-embryonic trophoblast lineages. The proliferative activity of estrogen-primed 
endometrium is inhibited by progesterone which induces the secretory activity in 
the glandular compartment followed by triggering the influx of specialized uterine 
natural killer cells such as uNK; CD16/CD56bright in response to the production 
of local chemokines such as CXCL9, CCL4 and CXCL10. The Uterine natural killer 
(uNK) cells which are a rich source of angiogenic and growth factors, has been 
reported to have critical role in remodeling of the endometrial spiral arteries during 
and prior to pregnancy [5, 30]. The contractile activity of the myocytes of the 
junctional zone is strongly reduced by the progesterone which is a crucial process 
for the apposition of the blastocyst to the luminal epithelium. The most outstand-
ing aspect of the maternal response during pregnancy is the transformation of the 
endometrial stromal fibroblasts into epithelioid-like, secretory decidual cells.
Upon implantation of a blastocyst, decidualization of the stromal compartment 
is observed in most species. On the other hand, in humans decidualization is initi-
ated without the involvement of a pregnancy in the midsecretory phase of the cycle. 
It is progressive process which is at first initiated around the terminal spiral arteries 
Figure 2. 
HPV clearance and non-clearance during pregnancy and postpartum.
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of the superficial endometrial layer which continues in pregnancy involving the 
entire endometrium as the pregnancy progresses [23]. The invasive or extravillous 
trophoblastic cells mediate the attachment of the placenta to the maternal uterine 
wall and they are responsible for the establishment of a low-resistance, high-flow 
supply of the maternal circulation to the fetus and the placenta. The placental 
dysfunction occurs due to the failed invasion of the extravillous trophoblast cells 
leading to the adverse obstetric outcomes such as spontaneous preterm delivery 
and pre-eclampsia. There are controversial reports on the HPV infection of the 
invasive trophoblast cells and their effects. There are reports showing the evidence 
of detection of HPV in trophoblast tissue from early pregnancy losses where HPV 
was more prominently found in spontaneous abortion cases than in cases of elective 
terminations of pregnancy. The genomes of the four different HPV types such as 
11, 18, 16 and 31 are reported to undergo complete life cycle in 3A trophoblast cell 
lines and the HPV-31 in an in vitro system are shown to decrease cell number of the 
trophoblast cell and their adhesion [31].
Impaired placental function is associated with pregnancy loss or complications 
such as abruption, fetal growth restriction and pre-eclampsia. In this case we have 
to consider that the uterine remodeling during pregnancy is required to accom-
modate deep trophoblast invasion and the decidual process is not primary under 
the embryonic control which makes the implantation process more vulnerable to 
perturbations in the mother [23].
4.  The possible mechanisms responsible for self-clearance and non-
clearance of HPV in pregnant women
4.1 Role of maternal immunity
Between the maternal decidua and the blastocyst the first point of contact is 
represented by the trophoblast. It has been reported by current studies that the 
trophoblast plays an active role during implantation and early placentation in 
shaping the immunological milieu by educating and attracting immune cells at the 
implantation site and thus modeling the subsequent response of the immune cells to 
external stimuli. Cytokines such as transforming growth factor-β (TGF β), CXCL12 
which is also known as SDF1, CXCL8 which is also known as IL-8 and CCL2 which 
is also known as MCP1 are constitutively secreted by trophoblast cells. The secre-
tion of these cytokines by trophoblast cells upon establishment at the implantation 
site, promotes the recruitment of neutrophils, peripheral monocytes, T cells, NK 
cells and Treg cells [32]. After decidualization although immune infiltrates are 
already present, studies have shown that for successful pregnancy, immune cell 
trafficking is crucial and any disruption in these chemokines signaling pathways 
leads to reduced infiltration of the immune cells and adverse pregnancy outcomes. 
Cytokines are also secreted by trophoblast cells that can act on immune cells after 
their recruitment. These secreted cytokines have been reported to stimulate the 
unique differentiation of the earlier recruited immune cells in such as a way that 
they acquire phenotypes which are collectively essential for the successful preg-
nancy [33].
Decidual NK cells are less cytotoxic, thus they are different from peripheral NK 
cells and TGFβ12 and trophoblast-derived IL-15 induces this type of phenotypes. 
Decidual vascular remodeling which is crucial for development of the placenta 
targeted by these specialized NK cells [34]. CD14+ monocytes upon recruitment to 
the maternal-fetal interface acquire a unique phenotype that is M2-like macrophage 
which might be induced by the trophoblast-derived macrophage colony-stimulating 
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factor (M-CSF) and IL-10 [2118]. These M2-like macrophages participate in 
clearance of apoptotic cells and phagocytosis of degraded extracellular matrix and 
play a crucial role in tissue remodeling [35]. Trophoblast-educated M2 like macro-
phages on the contrary to other tissue-resident macrophages, maintain their CD14 
expression and capable of immunomodulatory cytokine secretions such as type I 
interferons and TGFβ [35]. Trophoblast-derived TGFβ furthermore is able to induce 
the naive CD4+ cell differentiation into FOXP3+ Treg cells [36]. In addition to the 
trophoblast cells, a substantial amount of data have shown that the decidual cells 
also have vital role in regulation of the immune cell trafficking which is mostly T 
cells towards the site of implantation (Figure 3) [37, 38].
In addition to chemokines and cytokines secretion which attract and educate 
immune cells, numerous studies have shown that the trophoblast cells have the abil-
ity to sense and respond according to the microenvironment. Cell-surface receptors 
expressed by the trophoblast cells such as NOD-like receptors (NLRs) and TLRs 
can recognize specific molecular patterns within the microenvironment. These 
receptors have also the ability to recognize DAMPs which are basically released from 
damaged tissues and dying cells as well as PAMPs (Pathogen-associated molecular 
patterns) from viruses, bacteria and other microorganisms and thus permit the 
trophoblast cells to sense and response to these signals [39, 40]. Thus, the placental 
and fetal development is supported by the trophoblast cells attracting and educat-
ing immune cells and responding to the signals within the microenvironment in a 
unique way such as decidual differentiation followed by trophoblast migration and 
invasion, angiogenesis and finally spiral artery remodeling [41].
4.2 How pregnancy responses to viral infections
During pregnancy the consequences of viral infection can vary being a benign 
asymptomatic event which is undetected mostly and it can either cause the occur-
rence of fetal congenital malformations or pregnancy loss [42]. Like bacteria, the 
TLRs and NLRs expressed by the immune cells as well as those expressed by the 
trophoblast cells can be engaged by the viruses. Viral replication as well as vertical 
transmission of a virus to the developing fetus from the mother can also controlled 
by the trophoblast cells [43, 44]. Commensal bacteria which are present at the 
Figure 3. 
Immune modulation during pregnancy at the feto-maternal interface.
9Human Papilloma Virus Infections in Pregnant Women and Its Impact on Pregnancy Outcomes…
DOI: http://dx.doi.org/10.5772/intechopen.90197
feto-maternal interface can induce the secretion of IFNβ by trophoblast cells which 
supports the decidual receptivity by exerting immunomodulatory effects. It has been 
reported that the antiviral responses can be exerted by the IFNβ [45] and thus one of 
the molecular pathways that is type I IFN pathway is actively inhibited by the viruses 
as they establish as infection. Various studies in mouse model have demonstrated 
that by inhibiting IRF3 phosphorylating in the placenta, viral infection can decrease 
IFNβ expression which leads to the decreased antiviral responses [46]. TLR4 induced 
responses are modified by viral infections to commensal bacteria leading to the con-
version of pro-inflammatory from anti-inflammatory in nature [47]. The receptivity 
and tolerance at the feto-maternal interface is promoted by the IFNβ which suggests 
that blunted response of IFNβ secondary to viral infection is responsible for the det-
rimental pregnancy consequences. The reduced receptivity of the immune cells at the 
feto-maternal interface due to the loss of IFNβ also reduces their capacity to control 
and respond to other microorganisms. Thus, the association of the overwhelming 
inflammation with pregnancy complications suggests that there may be an involve-
ment of an undetected viral infection which can change the response pattern of the 
feto-maternal interface to commensal bacteria. This hypothesis has been supported 
by the study results of Cardenas et al. [48] using an animal model. In that study, 
pregnant C57BL/6 mice was infected with MHV68 on 8.5 embryonic day and a low 
dose of LPS subsequent administration on E15.5 day leads to a cytokine storm which 
was characterized by high levels of G-CSF, CXCL1, IL-8 and TNF which is associated 
with parturition, a reduced production of IFNβ followed by preterm birth. These 
changes in the cytokine profile leading to preterm birth is not induced alone either by 
LPS treatment or MHV68 infection but by a ‘double-hit hypothesis’ proposed by Mor 
et al. [41] which suggests that how trophoblast cells respond to bacterial products are 
changed by a viral infection which abolishes the normal microbiota immunomodula-
tory effects. In response of the commensal microbiota, the trophoblastic cells in 
the absence of a viral infection secret IFNβ, whereas IFNβ signaling is abolished in 
the presence of a viral infection leading to eradicate its immunomodulatory effects 
which in turn changes the response of the trophoblastic cells to commensal bacteria 
shifting IFNβ response to a cytokine storm which promotes preterm birth. However, 
it has been reported that the inflammation and preterm labour is also promoted 
either by an increased response of IFNβ or inhibition of the IFNβ regulators [49]. 
Thus, the original milieu which has a setting of immune-tolerance, during viral 
infection, is shifted into a state of pro-inflammatory condition [41].
4.3 Role of feto-maternal cell trafficking
During pregnancy there is a bidirectional cell passage exists between fetus 
and mother which is called feto-maternal cell trafficking. It is known as fetal 
microchimerism when there is a presence of fetal cells in the maternal circulation 
and maternal microchimerism when the maternal cells are present in the fetal 
circulation. Georg Schmorl in the year 1893 first reported about fetal microchi-
merism after identifying the placental trophoblast cells in a mother who died due 
to eclampsia [50]. The persistence of fetal cells in the maternal circulation [51, 52] 
and other maternal organs such as liver, heart, kidney [52] and bone marrow [53] 
has been reported decades after pregnancy. In 1963, with the identification of the 
maternal platelets and leukocytes in the cord blood the maternal microchimerism 
was described for the first time [54]. In healthy, immunocompetent individuals 
these maternal cells have been found to circulate into adult life [55].
At 7 weeks of pregnancy the bidirectional trafficking of the cells begins and 
increases throughout the gestation steadily and peaks at parturition [56]. In nor-
mal pregnancies, maternal microchimerism and fetal microchimerism has been 
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reported to be 42 and 51% respectively at the time of delivery [57]. In human blood 
and tissues the detection of maternal-fetal microchimerism is done by in situ 
hybridization for identification of whole cells and the identification of the origin 
of the DNA whether it is from mother or the fetus is done by polymerase chain 
reaction (PCR) to identify Y-chromosome DNA sequences in mother [58]. As the Y 
chromosome is easier to distinguish it is used as a biomarker to detect microchime-
rism and it does not require the fetus to be male. However, male microchimerism 
has been reported to be found in a fifth of women with no birth of a male child. The 
possible reason of the phenomenon can be a vanished male twin; early miscarriage 
of a male embryo; transfer of male cell through the maternal circulation from an 
older sibling to a later pregnancy; or due to an unexplored possibility of transfer of 
male DNA into the maternal circulation during sexual intercourse [59]. In females, 
male fetal cells have reported to show increased antigenicity. As the fetus carries 
paternal genes among which some are expressed on the cell surface that may induce 
potent allogeneic responses the mother confronts an immunological challenge 
during pregnancy. However, in spite of the immunologic differences of the cells, the 
fetus does not get rejected frequently (Figure 4) [60].
In pregnancy, the maternal and fetal cell exchange is common. During gesta-
tion, placenta allows the fetal and maternal reciprocal transport of cells in a state of 
mutual tolerance which proves placenta is not an immunologically inert barrier. It 
is not necessary to continue a pregnancy and deliver a child to develop mirochime-
rism. Up to 500,000 nucleated fetal cells can be delivered into the maternal circula-
tion even early terminations from surgical abortion [61, 62]. The cellular movement 
across the placental barrier is controlled by the maternal, fetal, or/and placental sig-
nals rather than nonspecific leakiness. The involvements of integrin-dependent and 
VEGF pathways are associated with the trans-placental cell trafficking mechanism 
but the initiation of the processes by the exact molecular signals are yet unknown 
[63]. In case of preeclampsia, fetal surgery and pregnancy termination where there 
is a disruption of the feto-maternal interface, association of altered feto-maternal 
cell trafficking has been reported which suggests that the placenta has a role in the 
cell migration regulation. The altered microchimerism levels are also associated 
with histocompatibility differences which suggests that the cell trafficking and 
the survival of the trafficked cells is either promoted or hindered by the immune 
response between the fetus and the mother [64, 65]. During pregnancy, the biologi-
cal role of the bidirectional movement of cells is unknown, although it has implica-
tions in the fetal immune system development [66]; repair of tissue in autoimmune 
disease [67–70] tolerance mechanisms during pregnancy [71]; immune surveillance 
Figure 4. 
Feto-maternal cell trafficking during pregnancy.
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[72] and cancer [73]. It is also involved in the maintenance of balance between the 
tolerance [74] and immunologic priming [75] which can influence the occurrence of 
autoimmune disease and transplantation outcomes. The utility of the feto-maternal 
cell trafficking has been identified clinically in the prediction of pregnancy compli-
cations [76, 77] and in prenatal testing for aneuploidies [78].
The research on microchimerism is still in its infancy, more specifically on the 
fetomaternal microchimerism. In women with autoimmune diseases, the long-term 
existence of the fetal cells and its speculative role has not yet been studied well. It 
has been reported by some of the researchers that the microchimeric cell popula-
tions occur due to pregnancy may have stem cell like properties which have the 
potential to home in damaged tissues and organs and further differentiate as part of 
the maternal repair response [62].
5. How HPV affects the pregnancy outcomes
Merckx et al. [79] reported that children born to HPV-positive mothers are 
at a significantly higher risk of becoming HPV positive which further results in 
infantile genital and anal condyloma acuminatum and juvenile laryngeal papillo-
matosis. However, by the age of 6 months some HPV infections are almost cleared. 
Hence, the question regarding susceptibility of pregnant women to HPV infection 
and its prevalence as compared to non-pregnant women population are crucial to 
answer [16].
Various studies reported that spontaneous abortion occurs in up to 30% of 
all pregnancies and it constitutes one of the most frequently occurring adverse 
pregnancy outcomes worldwide. In 5–13% of deliveries, spontaneous preterm birth 
is also observed [80]. As per the reports of recent investigations, the human papil-
lomavirus infection of the placenta may be involved with placental abnormalities, 
spontaneous preterm delivery and spontaneous abortion.
Trophoblast cells as discussed earlier constitute the prime target for HPV in 
placenta which is responsible for placentation abnormality. Various studies showed 
that in pregnant women the prevalence of HPV infection ranges widely from 6 to 
65% and the HPV DNA has been detected in amniotic fluid, placenta, fetal mem-
branes and umbilical cord blood [81].
Delivery before 37 weeks of gestation is defined as preterm birth and it is an 
important complication worldwide for both multifetal and singleton pregnancies. 
As compared to children born at term, the preterm children are more likely to 
develop log-term neurological and developmental disorders and are at an increased 
risk of mortality. The highest rates of preterm delivery have been reported to be 
found in South-eastern and South Asia with a percentage of 13.4%. Especially 
in low-income countries, the morbidity and mortality are highest among these 
preterm children [80].
As per the fetal origin of adult disease (FOAD) hypothesis, the specific changes 
in the fetus are caused by the intrauterine environmental exposures which lead 
to the risk of developing diseases in adult life. Depending on the environmental 
interaction, these risks may lead to adult diseases. Coronary heart disease was 
documented earlier to support this hypothesis [82] but a range of chronic condi-
tions has also now been included to expand the framework [83]. While, the ‘thrifty 
phenotype’ hypothesis states that low birth weight babies should not be at high risk 
of non-insulin dependent diabetes development when they grow with a scarcity 
of food [84, 85] but growing up in an area of affluence of the same babies would 
increase the risk and hence the intrauterine exposure plays an important role in 
inheriting the harmful potential in interaction with exposures later. Thus, the 
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reformulated FOAD hypothesis included epigenetics and the life –course epidemiol-
ogy as an important factor which includes social and physical exposures during ges-
tation, adolescence, childhood, young adulthood and adult life. To understand the 
development of chronic diseases, history specific and inter-generational elements 
of individual’s life is also important [86]. The timing of exposure variables and how 
the outcome of interest is related to each other is the basis of life-course perspective. 
Hence, the effects of intrauterine exposures can be modified by the entire lifespan 
of an individual through the life-events, behavioral, biological and socioeconomic 
processes [87].
Infection with HPV (Human papillomavirus) is generally regarded as sexually 
transmitted disease. However, the detection of HPV in the oral mucosa of newborn 
babies who are sexually inexperienced has been reported in various studies which 
suggests plausible non-sexual alternative route of HPV infection. Detection of 
HPV genotypes and their similarities in the offspring’s oral sample and in mother’s 
genital tract suggests that the probable source of HPV infection in the newborn is 
the HPV infected mother. In the mother-baby pair, the reported vertical transmis-
sion rates are between 18.2 and 53.3% [88].
The possible mode of vertical transmission of HPV to infant from a mother 
is still under debate. However, during fertilization, or pregnancy or delivery the 
possible mode of transmission has been implicated. Evidence of prenatal transmis-
sion of HPV has been provided by Koskimaa et al. [89] and the presence of HPV in 
cord blood and placenta has been shown to increase the risk of carrying HPV DNA 
in the oral mucosa which suggests that in the transmission of HPV, unlike several 
other human viruses, placenta may play an important role [27]. Recent studies 
reported that the placenta and the maternal microbiomes have role in regulating 
the neonatal microbiomes which suggests during pregnancy the fetal exposure of 
microbiota has long-term outcomes in their health [90]. The translocated maternal 
oral microbes are presented to the fetal immune system at the placenta which acts 
as a site leading to the development of prenatal tolerance to the maternal microbi-
ome [91].
The encounter with HPV and its significance in pre or perinatal period is not 
clear. Early exposure of HPV might have a significant impact in the HPV-specific 
immunity development, subsequent HPV infection and progression due to the 
immaturity of the immune system of the fetus and infant [92]. However, practically 
in children the HPV-specific immunity has remained an unknown area. As reported 
by Koskimaa et al. [88] and Koskimaa et al. [93], children aged 12–14 years had 
immunoreactivity specific to HPV 16 E2-, E6-, and E7. Whereas, various studies 
reported that the HPV-16 specific cell mediated immunity is much lower in adults 
[94, 95]. Between HPV positive and negative subjects, differences have been found 
in the memory Th cell (T Helper) reactivity against HPV16 E2, E7 and E6 oncopro-
teins in adults. Against HPV16 E2 and E6, the Th responsiveness is accompanied by 
the type 1 and type 2 cytokine secretions in a mixed pattern and seems to be more 
common in healthy individuals as compared to individuals with HPV16 induced 
disease.
Koskimaa et al. [89] reported that children those are exposed to HPV via cord 
blood or Oral HPV or placenta might have HPV16 specific T helper cell responses 
similar to the adults having HPV induced lesions which are highly different from 
negative HPV controls.
Though some studies have reported HPV infection to be associated with 
spontaneous preterm delivery and spontaneous abortion, controversy continues 
in this field due to the reason that some studies were unable to confirm this 
association.
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6.  Potential of HPV infection during pregnancy can lead to the 
development of cervical cancer and therapeutic strategies
Cervical cancer ranks as the 3rd most frequently diagnosed cancer with an 
estimated 569,847 incident cases and 311,365 deaths reported in the year 2018 
(GLOBOCAN) worldwide and in women it is the fourth leading cause of death 
due to cancer. After breast cancer it ranks second in incidence and mortality rates 
in lower HDI settings. Worldwide in 28 countries it is the mostly diagnosed cancer 
and leading cause of cancer death in 42 countries which includes vast majority in 
South-Eastern Asia and Sub-Saharan Africa [96]. It has been reported that around 
530,000 women get affected every year by cervical cancer and the HPV related 
cancer burden in women worldwide add up to 6% of total cancer cases.
In India, the diagnosis of new cervical cancer is about 96,922 cases annually 
making it the 2nd leading cause of female cancer. Women aged between 15 and 
44 years, cervical cancer is the second most common female cancer in India [97].
The development of cervical cancer and its precursor lesions are reported 
through several epidemiological and biological studies to be associated with high-
risk human papilloma virus (HPV) infection. The development of high grade 
cervical lesions is reported to be associated with positive high-risk HPV test results 
in women with or without abnormal cervical smears [66, 98–100]. It has been 
reported in various studies on immunocompromised patients such as transplant 
recipients and AIDs patients that the increased persistence of high-risk HPV and 
HPV-mediated carcinogenesis is associated with compromised immunosurveil-
lance [101, 102]. In pregnancy, the immune-response is altered in women and some 
studies concluded that there is no effect of pregnancy on CIN [103], whereas few 
reported high relapse rates of cervical dysplasia in the postpartum period [104]. 
Likewise, few studies reported high-risk HPV prevalence rate to be higher in preg-
nant women and others reported there is no difference of HPV prevalence between 
non-pregnant and pregnant women. However, on the natural course of high-risk 
HPV types infection the influence of pregnancy is not yet known. There are few 
questions need to be answered in this area: (1) what is the difference between the 
clearance of HPV in pregnant and non-pregnant women? (2) During pregnancy 
how does the high-risk HPV rate change? [6].
The Food and Drug Administration (FDA) has approved three vaccines such 
as the first-generation human papillomavirus (HPV) vaccines, Gardasil (Merck, 
Kenilworth, NJ, USA) which is a quadri valent vaccine; Cervarix (GlaxoSmithKline, 
London, UK) which is a bivalent vaccine, have the potential to prevent about 70 and 
84% of the cervical cancer cases respectively. Gardasil 9 (Merck), which is a next-
generation nonavalent HPV vaccine, can prevent cervical cancer approximately 
90%. However, pre-existing infections and their related cervical abnormalities 
cannot be treated by these vaccines. The American Society of Clinical Oncology 
(ASCO) in the year 2016 released cervical screening guidelines which recom-
mend the screening for women aged between 30 and 49 years, one to three times 
in a lifetime in lower resource settings [105]. The screening should be done with 
primary HPV testing via the use of self-collected specimens as it has been reported 
to be more effective, adaptable and reliable method of screening as compared to 
traditional cytological methods and thus the effective cervical cancer screening can 
be done in several generations of women [106].
In terms of HPV vaccination and coverage rates of cervical screening, consider-
able inconsistencies exist worldwide between countries and within countries. In 
low-income and middle-income countries (LMICs), in the year 2008 the reported 
overall screening uptake was 19%, while in high-income regions it was 63% [107]. 
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As compared to high-income countries, in low-income and middle-income coun-
tries the HPV vaccination coverage is much lower. In the high-income countries an 
estimated 33.6% of girls and women aged between 10 and 20 years had received 
the full course of HPV vaccine by the year 2014 as compared to low-income and 
middle-income countries which was 2.7% of the same age group of females [108]. 
Though studies are still in progress on the long-term vaccine efficacies to under-
stand the total duration of protection, it has been reported that with Gardasil the 
protection against targeted HPV types last for at least 10 years [109], with Cervarix 
at least 9 years [110] and with Gardasil 9 a least 6 years [111]. But these vaccines 
have not sufficiently been tested during pregnancy and hence it is not used in 
pregnant women.
The Centers for Disease Control and Prevention (CDC) recommends HPV 
vaccination for women having either an HPV infection or an abnormal Pap test or 
both if they are in the appropriate age group as that may protect them against the 
high-risk HPV types which have not been acquired by them. However, the vaccina-
tion has not the potential to treat the abnormal results of the Pap test or cure the 
current HPV infections [112]. Though, the vaccines have been reported to be safe 
when given to people with pre-existing HPV infection, it gives maximum benefit 
if given to people before being sexually active [113, 114]. However, some residual 
benefit from the vaccination will still be there for people already exposed to HPV 
even though infections with one or more HPV types which are included in the vac-
cines. Currently, there is no specific test available to detect past exposure of HPV in 
individuals and the approved HPV tests detect only current infection with high-risk 
HPV types at the cervix region without any information on past infection.
Even after the vaccination, the screening for cervical cancer need to be done as 
all HPV types which has the potential to cause cancer are not covered by the HPV 
vaccines. Therefore, in cervical cells to detect precancerous changes before the 
development of cancer, screening is essential. Additionally, women with exist-
ing HPV infection or who are not vaccinated the cervical screening is critically 
important. However, the screening recommendations may be changed in future for 
women given HPV vaccination.
Research works are in progress to develop therapeutic HPV vaccines which 
would prevent cancer development among women with previous history of HPV 
infection. The immune system will be stimulated by these vaccines which will result 
in specifically targeting and killing infected cells. The safety and efficacy of a thera-
peutic DNA vaccine are being tested by ongoing clinical trials to treat HPV related 
cervical and vulvar lesions [115–117]. A combination of preventive and therapeutic 
vaccine would be an ideal strategy in this case.
Topical microbicides is another preventive strategy which is being explored. 
In various studies, carrageenan which is an extracted compound from seaweed 
widely used in foods and other products has been reported to inhibit infection 
with HPV. Clinical trial in healthy individuals with a gel containing carrageenan is 
underway to test its efficacy to prevent genital HPV infections.
6.1 Immunization of the pregnant women
The response of the adaptive immune system of the infants cannot be protective 
to many pathogens in the first months of life. The T cells of both fetal and neonatal 
origin are shewed towards Th2 responses which are ineffective against intracellular 
pathogens. Ineffectiveness has also been reported for bacterial polysaccharides 
by antibody responses. Infants rely on additional protection during this period 
which is acquired from maternal antibodies during gestation passively transported 
through the placenta. At the time of birth, the antibody levels present in the infants 
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are correlated with the maternal antibody levels and the therefore, there is an 
interconnection between the antibody levels present in the maternal circulation 
and the degree of transfer of antibodies. However, the suboptimal maternal specific 
antibodies may not be sufficient to provide full protective immunity or can provide 
protection only for a limited period of time to the infants. Moreover, the maternal 
antibody levels decrease over a periods of approximately 6 months after birth. 
Therefore, the aim of the maternal immunization is to increase the concentration 
of maternal specific antibody and their passive transport to the fetus which will 
reduce the window of vulnerability for infants. IgG (Immunoglobulin G) is the only 
isotype among the five antibody classes that has the ability to efficiently cross the 
human placenta. Syncytiotrophoblast cells of the placenta, are responsible for the 
transfer of the IgG antibodies from mother to the fetus, which are located in contact 
with the maternal blood. In the circulation maternal IgG are internalized in endo-
somes and bind to Fc receptors (FcRn) of the neonatal cells which are expressed 
on the surface of the internal endosomes. On membrane of the fetal side of the 
syncytiotrophoblasts, the endosomes fuse and the IgG are released from FcRn. 
Passing through the villous stroma and fetal capillary endothelium, IgG enters the 
fetal circulation through an unknown mechanism. With the largest transferred 
proportion during the third trimester of pregnancy, the transfer of IgG through 
placenta increases over time especially within the last 4 weeks. Consistent with an 
active transport process, the IgG concentration in the fetal circulation are gener-
ally greater than the maternal circulation at full term of pregnancy [118, 119]. This 
transfer is influenced by several factors such as maternal non-infectious diseases, 
placental integrity, total maternal IgG concentration, FcRn availability, IgG sub-
type, timing of infection or vaccination and nature of the antigen [120]. IgG4, IgG3 
and IgG2 are the least efficiently transferred to the fetus as compared to IgG1 which 
is the most efficiently transferred antibody subtype to the fetus.
Approximately after 2 weeks of maternal immunization, the concentration 
of specific antibodies starts increasing which suggests that if the vaccination is 
provided between 28 and 32 weeks of pregnancy, the optimal amount of specific 
IgG may be achieved in full-term infants at birth, but may not be the same for 
preterm infants. Diphtheria toxoid-acellular pertussis vaccine (Tdap) in the second 
trimester is reported to be reduced by the vaccination with tetanus toxoid which 
results in higher neonatal anti-pertussis antibody titers as compared to vaccina-
tion in the third trimester both in preterm and term neonates [121, 122]. The total 
longer transfer time may be a reason for the accumulation of antibodies in the fetal 
circulation. In addition to the maternal IgG antibodies which is transferred through 
placenta and known for providing protection, lesser concentration of IgG, IgM 
and high concentration of maternal IgA are also excreted in the breast milk and 
colostrum [123]. Immediately after delivery or in the second or third trimester of 
pregnancy, vaccination with Tdap reported to increase the pertussis-specific IgA 
antibody levels in the breast milk [124]. Therefore, another mode of transferring 
antibodies to the new born is breastfeeding. The maternal IgA transferred through 
the breast milk helps protecting the infants against enteric infections and respira-
tory illness with fever in infants born to influenza-vaccinated mothers for at least 
6 months after birth [42, 123]. Though, there are evidences highlighting the mater-
nal immunization benefits, few studies have also shown controversial interferences 
between the maternal IgG antibodies and the infant antibody responses [125].
The “immunological blunting”, a phenomenon is observed after the primary 
vaccination series in early infancy when the maternal IgG antibodies can inhibit 
the immune responses against the same or related antigens. While after the booster 
dose, this blunting effect dissipates [119, 126]. Blunting has been reported to be 
observed with polio and measles vaccines after natural infection or maternal 
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immunization for maternal antibodies [119, 127]. Though, the clinical importance 
of this blunting effect is unknown, the epidemiological data of implemented 
maternal immunization from various countries have not shown any negative impact 
on the protection against the diseases targeted [26, 128].
6.2 HPV vaccination during pregnancy
Gardasil and Cervarix both HPV vaccines are recombinant which contains 
virus-like particles (VLP’s) and enhanced by an adjuvant which is responsible for 
triggering an immune response higher than a natural infection [129]. Gardasil 9, a 
9-valent HPV vaccine was only licensed for use in the USA in December 2014.
Depending on age, full coverage by the HPV vaccine is obtained by 2 or 3 
doses with the first dose administered at time o, followed by the second dose 
after 1–2 months and the third dose after 6 months [130]. While, all doses are not 
received by many girls [131]. In order to achieve long-term duration of immunity, 
the repeat doses of vaccine are given which boost the immune system.
Worldwide, millions of doses of HPV vaccine since its introduction have been 
administered and involuntary administration also occurs during pregnancy as the 
young fertile women are the main recipients of the vaccines. Potentially harmful 
adverse effects (AE) to the unborn child such as preterm birth, miscarriage, con-
genital malformations, fetal death or fears of teratogenicity raise concern among 
both the health care providers and recipients. The development of sensitive organs 
such as the heart, the central nervous system takes place in the first trimester of 
pregnancy and in this period the environmental factors like medications and drugs 
theoretically might cause damage the developing fetus which is the main reason of 
concern. The vaccine manufacturers (Merck and GlaxoSmithKline) and the World 
Health Organization recommend avoiding HPV vaccination during pregnancy [36]. 
However, in case of accidental vaccination of pregnant women there are no inter-
ventions and no mandatory pregnancy testing before vaccination recommended so 
far. Moreover, conducting studies to investigate the pregnancy outcomes by admin-
istering HPV vaccines to pregnant women are not ethically feasible. In pregnancy, 
the true safety of the HPV vaccination has not yet been established through ran-
domized controlled trial. Hence, the HPV vaccine administration to the pregnant 
women has not yet been approved [132].
7. Conclusion
In pregnant women, many observational studies reported the HPV infection risk 
but there are controversial results too. Higher HPV prevalence has been reported in 
few studies, whereas several studies reported lower prevalence in pregnant women 
or there is no statistical difference between pregnant and age matched non-preg-
nant controls [16].
For a successful pregnancy, a modulated, dynamic and responsive immune 
system is required but definitely not a suppressive one and this has been sup-
ported by an increasing number of studies. At the feto-maternal interface, the 
trophoblastic cells are important for the receptive immune system establishment 
which is achieved as a part of response mechanism to the normal microbiota which 
highlights the complexity of the regulatory pathways involved during pregnancy. 
Moreover, there are evidences on the effects that changed the modulated immune 
system and the receptive feto-maternal interface by a clinically silent viral infection 
emphasizes the necessity of better detection, treatment and prevention of the viral 
infections during pregnancy. This will further lead not only to the better outcomes 
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of pregnancy but also the postnatal development can be affected in a better way as 
these viral infections and the subsequent inflammations reported to be associated 
with mental health issues and diseases of the immune system such as asthma and 
allergies. The effects of viral infections on fetal development during pregnancy can 
more be exemplified by the recent Zika virus outbreak and its teratogenic effect on 
the development of brain [22]. Therefore, it is important to understand the complex 
immune responses during pregnancy, with the continued risk of pandemics and the 
emergence of newer diseases associated as secondary to the viral infection, which 
will lead to the development of appropriate approaches and tools to protect both the 
fetus and the mother [41].
Moreover, there are very limited data is available due to the very limited number 
of investigations have been performed on materials from spontaneous abortions 
and spontaneous preterm deliveries due to HPV infection and the heterogeneous 
study groups making it difficult to come to a reliable conclusion. A proper study 
design, selection of proper controls is very essential in this case and a strict control 
of the similarity in patients/samples is needed for a valuable comparison between 
studies. Furthermore, the simple detection of a virus cannot be a real causative role 
for diseases in general or adverse pregnancy outcomes. Therefore, for this particular 
situation it is important to study the cellular localization and the viral activity to 
come to a realistic conclusion.
Therefore, we recommend more investigations on materials of adverse preg-
nancy outcomes including spontaneous abortion and spontaneous preterm delivery 
and the molecular mechanism of HPV infections on it which is the need of the hour 
and researchers need to conduct new studies to clarify the exact molecular mecha-
nisms involved on the HPV infection in early pregnancy and how the self-clearance 
takes place during the course of pregnancy.
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